
This has been an eventful year for Medi-Cal administrative hearings due to a wave of Medicaid investigations of pharmacies. (I covered it in this blog post). Every hearing that my firm handled this year involved the same fundamental problem: a pharmacy billed one National Drug Code (NDC) but dispensed medication bearing a different NDC.
Although NDC discrepancies may appear to be minor billing errors, they can lead to audit chargebacks, administrative disputes, monetary penalties, and, in the most serious cases, allegations of insurance fraud. Pharmacies should understand the three common scenarios in which these discrepancies arise.
Three Types of NDC Discrepancies
The cases generally fall into three categories:
- The pharmacy bills one NDC but dispenses the same drug under an NDC that differs only in the final two digits, which identify the package or bottle size.
- The pharmacy bills one NDC but dispenses a therapeutically equivalent drug under a different NDC, then inadvertently fails to reverse and rebill the claim.
- The pharmacy intentionally bills one NDC while dispensing another product—for example, billing for a brand-name drug but dispensing a generic equivalent.
I handled cases involving all three scenarios this year. In prior audits, the California Department of Health Care Services (DHCS), like the California State Board of Pharmacy, did not appear to focus as closely on NDC-specific discrepancies. More recent cases, however, demonstrate that pharmacies should no longer assume that different NDCs for the same drug will be treated as interchangeable.
Package Size Still Matters
Many of this year’s cases involved NDCs that differed only by package size. Our position was straightforward: a pharmacy should not face a full disallowance when it dispensed the same drug, in the same strength, from the same manufacturer, but used a bottle size different from the one associated with the billed NDC.
In each case, we asked DHCS to combine NDCs that differed only in their final two digits. Those digits identify package size, while the drug, strength, and manufacturer remain unchanged. We also argued that the discrepancy did not increase reimbursement because, in the claims at issue, reimbursement was calculated on a per-unit basis rather than by the bottle size reflected in the final two NDC digits.
This issue often arises from practical inventory constraints. For example, a prescription may call for 90 tablets, but the pharmacy may have only a 30-count bottle available when the patient needs the medication. The pharmacy might dispense the available quantity and provide the balance shortly afterward. The billing system, however, may not accommodate the transaction in a way that accurately reflects the package sizes actually used.
DHCS has expressed concern that manufacturer rebates are tied to specific NDCs. Whatever the reimbursement impact of a package-size discrepancy may be, the operational lesson is clear: pharmacies should verify that the package size associated with the billed NDC matches the product actually dispensed. Until DHCS adopts a different approach, even a difference limited to the final two digits can create significant audit exposure.
A more proportionate audit policy would distinguish package-size discrepancies from cases involving different drugs, strengths, or manufacturers. At a minimum, pharmacies that dispensed the correct drug should not automatically lose the entire ingredient cost solely because of a package-size mismatch.
Reverse and Rebill When the Product Changes
The second scenario is common and usually preventable. A pharmacy bills a claim using one NDC but ultimately dispenses the same drug from a different manufacturer or dispenses a therapeutically equivalent product. Staff then forget to reverse the original claim and rebill it using the NDC that was actually dispensed.
The best protection is a consistent verification process. Pharmacy personnel should compare the NDC on the product being dispensed with the NDC submitted on the claim. If the product changes after the claim is processed, staff should promptly reverse and rebill the claim using the correct NDC. Training, written procedures, and a final NDC check can prevent a routine substitution from becoming a costly audit finding.
Billing Brand and Dispensing Generic Creates the Greatest Risk
The third scenario is the most serious: intentionally billing for a brand-name drug while dispensing a generic product. This practice can expose a pharmacy to allegations of insurance fraud, as well as chargebacks and monetary penalties.
Severe reimbursement pressures may help explain why some independent pharmacies make risky billing decisions, but they do not eliminate the consequences. One pharmacy reported that reimbursement for a particular drug fell from $152.13 to $24.30 in a single month—a devastating reduction for an independent pharmacy. Even under those conditions, billing for a product that was not dispensed creates substantially greater financial and legal risk. The billed NDC must accurately reflect the product provided to the patient.
The Bottom Line
NDC accuracy is no longer a minor administrative detail. Pharmacies should ensure that the billed NDC matches the drug, manufacturer, and package size actually dispensed; reverse and rebill claims whenever the product changes; and never bill for a brand-name drug while dispensing a generic. Careful staff training, reliable verification procedures, and prompt correction of claim errors can reduce audit exposure and protect the pharmacy from chargebacks, penalties, and allegations of fraud. In an increasingly difficult reimbursement environment, precise NDC billing is both a compliance obligation and an essential business safeguard.









